Wu Richard Y, Liu Amy Y, Sio Terence T, Blanchard Pierre, Wages Cody, Amin Mayankkumar V, Gunn Gary B, Titt Uwe, Ye Rong, Suzuki Kazumichi, Gillin Michael T, Zhu Xiaorong R, Mohan Radhe, Frank Steven J
Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Int J Part Ther. 2017 Fall;4(2):26-34. doi: 10.14338/IJPT-17-00010.1. Epub 2017 Dec 28.
The authors aimed to illustrate the potential dose differences to clinical target volumes (CTVs) and organs-at-risk (OARs) volumes after proton adaptive treatment planning was used.
The records of 10 patients with oropharyngeal cancer were retrospectively reviewed. Each patient's treatment plan was generated by using the Eclipse treatment planning system. Verification computed tomography (CT) scan was performed during the fourth week of treatment. Deformable image registrations were performed between the 2 CT image sets, and the CTVs and major OARs were transferred to the verification CT images to generate the adaptive plan. We compared the accumulated doses to CTVs and OARs between the original and adaptive plans, as well as between the adaptive and verification plans to simulate doses that would have been delivered if the adaptive plans were not used.
Body contours were different on planning and week-4 verification CTs. Mean volumes of all CTVs were reduced by 4% to 8% ( ≤ .04), and the volumes of left and right parotid glands also decreased (by 11% to 12%, ≤ .004). Brainstem and oral cavity volumes did not significantly differ (all ≥ .14). All mean doses to the CTV were decreased for up to 7% ( ≤ .04), whereas mean doses to the right parotid and oral cavity increased from a range of 5% to 8% ( ≤ .03), respectively.
Verification and adaptive planning should be recommended during the course of proton therapy for patients with head and neck cancer to ensure adequate dose deliveries to the planned CTVs, while safe doses to OARs can be respected.
作者旨在说明使用质子适形治疗计划后,临床靶区(CTVs)和危及器官(OARs)体积的潜在剂量差异。
回顾性分析10例口咽癌患者的记录。每位患者的治疗计划均使用Eclipse治疗计划系统生成。在治疗的第四周进行验证计算机断层扫描(CT)。在两组CT图像之间进行可变形图像配准,并将CTVs和主要OARs转移到验证CT图像上以生成适形计划。我们比较了原始计划与适形计划之间以及适形计划与验证计划之间CTVs和OARs的累积剂量,以模拟如果不使用适形计划将会给予的剂量。
计划CT和第4周验证CT上的身体轮廓不同。所有CTVs的平均体积减少了4%至8%(≤0.04),左右腮腺的体积也减小了(分别减少11%至12%,≤0.004)。脑干和口腔体积无显著差异(均≥0.14)。CTV的所有平均剂量降低了多达7%(≤0.04),而右侧腮腺和口腔的平均剂量分别增加了5%至8%(≤0.03)。
对于头颈癌患者,在质子治疗过程中应推荐进行验证和适形计划,以确保向计划的CTVs给予足够的剂量,同时保证对OARs的安全剂量。